Targeting eIF4A using rocaglate CR‑1‑31B sensitizes gallbladder cancer cells to TRAIL‑mediated apoptosis through the translational downregulation of c‑FLIP

Cao,Yang; He,Ying; Yang,Litao; Luan,Zhou

doi:10.3892/or.2020.7856

Targeting eIF4A using rocaglate CR‑1‑31B sensitizes gallbladder cancer cells to TRAIL‑mediated apoptosis through the translational downregulation of c‑FLIP

Authors:
- Yang Cao
- Ying He
- Litao Yang
- Zhou Luan
View Affiliations

Affiliations: Department of Gastric Surgery, Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, P.R. China, Department of Ophthalmology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430014, P.R. China, Department of Gastroenterology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, P.R. China
Published online on: November 17, 2020 https://doi.org/10.3892/or.2020.7856
Pages: 230-238
Copyright: © Cao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Induction of the apoptosis of tumor cells is a promising therapeutic approach for the treatment of cancer. Tumor necrosis factor‑related apoptosis‑inducing ligand (TRAIL) is a novel type of anticancer drug. However, gallbladder cancer cells (GBC) exhibit strong resistance to TRAIL. The aim of the present study was to assess the effect of rocaglate CR‑1‑31B (CR‑31), an inhibitor of eukaryotic translation initiation factor 4A (eIF4A), on the sensitization of cells to TRAIL‑induced apoptosis in TRAIL‑resistant GBC. eIF4A was highly abundant in GBC tissues and cell lines (GBC‑SD and SGC‑996). GBC cells were treated using TRAIL and/or CR‑31 and then apoptosis and TRAIL signaling were detected in vitro. CR‑31 enhanced the sensitivity of TRAIL‑resistant GBC cells, due to the CR‑31‑mediated eIF4A translational downregulation of c‑FLIP and the subsequent activation of the caspase cascade. Furthermore, GBC‑SD tumor xenografts models were established and the effects of CR‑31 in vivo were assessed. CR‑31 significantly reduced the growth and initiated the apoptosis of tumor cells, suggesting that CR‑31 also increased sensitivity in vivo. Taken together, the results of the present study show that CR‑31 treatment countered the resistance to TRAIL in GBC cells in vitro and in vivo. Therefore, eIF4A may serve as a novel therapeutic target and its combination with TRAIL‑CR‑31 as a therapy may serve as a novel strategy for GBC treatment.

View Figures

View References

1	Baichan P, Naicker P, Devar JWS, Smith M, Candy GP and Nweke E: Targeting gallbladder cancer: A pathway based perspective. Mol Biol Rep. 47:2361–2369. 2020. View Article : Google Scholar
2	Maurya SK, Tewari M, Mishra RR and Shukla HS: Genetic aberrations in gallbladder cancer. Surg Oncol. 21:37–43. 2012. View Article : Google Scholar
3	Henry CM and Martin SJ: Caspase-8 acts in a non-enzymatic role as a scaffold for assembly of a pro-inflammatory ‘FADDosome’ complex upon TRAIL stimulation. Mol Cell. 65:715–729.e5. 2017. View Article : Google Scholar
4	Merino D, Kelly GL, Lessene G, Wei AH, Roberts AW and Strasser A: BH3-mimetic drugs: Blazing the TRAIL for new cancer medicine. Cancer Cell. 34:879–891. 2018. View Article : Google Scholar
5	Zhu W, Zhan D, Wang L, Ma D, Cheng M, Wang H, Zhao J, Cai Y and Cheng Z: Proteasome inhibitor MG132 potentiates TRAIL-induced apoptosis in gallbladder carcinoma GBC-SD cells via DR5-dependent pathway. Oncol Rep. 36:845–852. 2016. View Article : Google Scholar
6	Srivastava K, Srivastava A and Mittal B: Caspase-8 polymorphisms and risk of gallbladder cancer in a northern Indian population. Mol Carcinog. 49:684–692. 2010.
7	Zong H, Yin B, Chen J, Ma B, Cai D and He X: Over-expression of c-FLIP confers the resistance to TRAIL-induced apoptosis on gallbladder carcinoma. Tohoku J Exp Med. 217:203–208. 2009. View Article : Google Scholar
8	Bhat M, Robichaud N, Hulea L, Sonenberg N, Pelletier J and Topisirovic I: Targeting the translation machinery in cancer. Nat Rev Drug Discov. 14:261–278. 2015. View Article : Google Scholar
9	Iwasaki S, Floor SN and Ingolia NT: Rocaglates convert DEAD-box protein eIF4A into a sequence-selective translational repressor. Nature. 534:558–561. 2016. View Article : Google Scholar
10	Chu J, Zhang W, Cencic R, Devine WG, Beglov D, Henkel T, Brown LE, Vajda S, Porco JA Jr and Pelletier J: Amidino-rocaglates: A potent class of eIF4A inhibitors. Cell Chem Biol. 26:1586–1593.e3. 2019. View Article : Google Scholar
11	Langlais D, Cencic R, Moradin N, Kennedy JM, Ayi K, Brown LE, Crandall I, Tarry MJ, Schmeing M, Kain KC, et al: Rocaglates as dual-targeting agents for experimental cerebral malaria. Pro Natl Acad Sci USA. 115:E2366–E2375. 2018. View Article : Google Scholar
12	Rodrigo CM, Cencic R, Roche SP, Pelletier J and Porco JA: Synthesis of rocaglamide hydroxamates and related compounds as eukaryotic translation inhibitors: Synthetic and biological studies. J Med Chem. 55:558–562. 2012. View Article : Google Scholar
13	Luan Z, He Y, Alatar M, Chen Z and He F: Targeting the prohibitin scaffold-CRAF kinase interaction in RAS-ERK-driven pancreatic ductal adenocarcinoma. Mol Cancer. 13:382014. View Article : Google Scholar
14	Collisson EA, Trejo CL, Silva JM, Gu S, Korkola JE, Heiser LM, Charles RP, Rabinovich BA, Hann B, Dankort D, et al: A central role for RAF-MEK-ERK signaling in the genesis of pancreatic ductal adenocarcinoma. Cancer Discov. 2:685–693. 2012. View Article : Google Scholar
15	Kong X, Luo J, Xu T, Zhou Y, Pan Z, Xie Y, Zhao L, Lu Y, Han X, Li Z and Liu L: Plumbagin enhances TRAIL-induced apoptosis of human leukemic Kasumi-1 cells through upregulation of TRAIL death receptor expression, activation of caspase-8 and inhibition of cFLIP. Oncol Rep. 7:3423–3432. 2017. View Article : Google Scholar
16	Hayakawa Y, Screpanti V, Yagita H, Grandien A, Ljunggren HG, Smyth MJ and Chambers BJ: NK cell TRAIL eliminates immature dendritic cells in vivo and limits dendritic cell vaccination efficacy. J Immunol. 172:123–129. 2004. View Article : Google Scholar
17	Rawla P, Sunkara T, Thandra KC and Barsouk A: Epidemiology of gallbladder cancer. Clin Exp Hepatol. 5:93–102. 2019. View Article : Google Scholar
18	Wu K, Huang J, Lin N, Xu T, Cai W and Ye Z: Antitumor effect of ginsenoside Rg3 on gallbladder cancer by inducing endoplasmic reticulum stress-mediated apoptosis in vitro and in vivo. Oncol Lett. 16:5687–5696. 2018.
19	Song X, Wang Z, Liang H, Zhang W, Ye Y, Li H, Hu Y, Zhang Y, Weng H, Lu J, et al: Dioscin induces gallbladder cancer apoptosis by inhibiting ROS-mediated PI3K/AKT signalling. Int J Bio Sci. 13:782–793. 2017. View Article : Google Scholar
20	Chu J, Galicia-Vázquez G, Cencic R, Mills JR, Katigbak A, Porco JA Jr and Pelletier J: CRISPR-mediated drug-target validation reveals selective pharmacological inhibition of the RNA helicase, eIF4A. Cell Rep. 15:2340–2347. 2016. View Article : Google Scholar
21	Zhang W, Chu J, Cyr AM, Yueh H, Brown LE, Wang TT, Pelletier J and Porco JA Jr: Intercepted retro-nazarow reaction: Syntheses of amidino-rocaglate derivatives and their biological evaluation as eIF4A inhibitors. J Am Chem Soc. 141:12891–12900. 2019. View Article : Google Scholar
22	Tsumuraya T, Ishikawa C, Machijima Y, Nakachi S, Senba M, Tanaka J and Mori N: Effects of hippuristanol, an inhibitor of eIF4A, on adult T-cell leukemia. Biochem Pharmacol. 81:713–722. 2011. View Article : Google Scholar
23	Nazim UM and Park SY: Attenuation of autophagy flux by 6-shogaol sensitizes human liver cancer cells to TRAIL-induced apoptosis via p53 and ROS. Int J Mol Med. 43:701–708. 2019.
24	Min KJ, Han MA, Kim S, Park JW and Kwon TK: Osthole enhances TRAIL-mediated apoptosis through downregulation of c-FLIP expression in renal carcinoma Caki cells. Oncol Rep. 37:2348–2354. 2017. View Article : Google Scholar
25	Hughes MA, Powley IR, Jukes-Jones R, Horn S, Feoktistova M, Fairall L, Schwabe JW, Leverkus M, Cain K and MacFarlane M: Co-operative and hierarchical binding of c-FLIP and caspase-8: A unified model defines how c-FLIP isoforms differentially control cell fate. Mol Cell. 61:834–849. 2016. View Article : Google Scholar
26	Huang Y, Yang X, Xu T, Kong Q, Zhang Y, Shen Y, Wei Y, Wang G and Chang KJ: Overcoming resistance to TRAIL-induced apoptosis in solid tumor cells by simultaneously targeting death receptors, c-FLIP and IAPs. Int J Oncol. 49:153–163. 2016. View Article : Google Scholar
27	Zong H, Zhou H, Xiang Y and Wu G: miR-125b suppresses cellular proliferation by targeting c-FLIP in gallbladder carcinoma. Oncol Lett. 18:6822–6828. 2019.
28	Su W, Jiang X, Chen M, Huang M, Tang N, Wang X, Li X, She F and Chen Y: cIAP1 promotes proliferation and migration and prevents apoptosis in gallbladder cancer in vitro. Biosci Rep. 39:BSR201822662019. View Article : Google Scholar